Abstract
Substantial evidence indicates that neuroactive kynurenine metabolites play a role in the normal physiology of the human brain, and are involved in the pathology of neurodegenerative disorders such as Parkinsons disease and Huntingtons disease. A side-arm product of the pathway, kynurenic acid (KYNA), which is synthesized by the irreversible transamination of kynurenine (KYN) by kynurenine aminotransferases (KAT I and KAT II), is an excitatory amino acid receptor antagonist. In the present study, we measured the level of KYNA and the activities of the biosynthetic enzyme isoforms KAT I and KAT II in the plasma and in the erythrocytes (RBCs) of patients with cervical dystonia or blepharospasm and in age-matched controls. The KAT I and KAT II activities were significantly lower in the plasma of the patients in both subgroups. In the RBCs, only the KAT I activity was elevated significantly. The KYNA concentration was unchanged in both type of patients. These data support the contribution of an altered kynurenine metabolism to the pathogenesis of focal dystonia.
Keywords: Cervical dystonia, blepharospasm, kynurenine aminotransferase, kynurenic acid, excitotoxicity
Medicinal Chemistry
Title: Peripheral Kynurenine Metabolism in Focal Dystonia
Volume: 3 Issue: 3
Author(s): Zsuzsanna Hartai, Peter Klivenyi, Tamas Janaky, Botond Penke, Laszlo Dux and Laszlo Vecsei
Affiliation:
Keywords: Cervical dystonia, blepharospasm, kynurenine aminotransferase, kynurenic acid, excitotoxicity
Abstract: Substantial evidence indicates that neuroactive kynurenine metabolites play a role in the normal physiology of the human brain, and are involved in the pathology of neurodegenerative disorders such as Parkinsons disease and Huntingtons disease. A side-arm product of the pathway, kynurenic acid (KYNA), which is synthesized by the irreversible transamination of kynurenine (KYN) by kynurenine aminotransferases (KAT I and KAT II), is an excitatory amino acid receptor antagonist. In the present study, we measured the level of KYNA and the activities of the biosynthetic enzyme isoforms KAT I and KAT II in the plasma and in the erythrocytes (RBCs) of patients with cervical dystonia or blepharospasm and in age-matched controls. The KAT I and KAT II activities were significantly lower in the plasma of the patients in both subgroups. In the RBCs, only the KAT I activity was elevated significantly. The KYNA concentration was unchanged in both type of patients. These data support the contribution of an altered kynurenine metabolism to the pathogenesis of focal dystonia.
Export Options
About this article
Cite this article as:
Hartai Zsuzsanna, Klivenyi Peter, Janaky Tamas, Penke Botond, Dux Laszlo and Vecsei Laszlo, Peripheral Kynurenine Metabolism in Focal Dystonia, Medicinal Chemistry 2007; 3 (3) . https://dx.doi.org/10.2174/157340607780620707
DOI https://dx.doi.org/10.2174/157340607780620707 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Chemistry and Pharmacological Properties of Some Natural and Synthetic Antioxidants for Heavy Metal Toxicity
Current Medicinal Chemistry Recent Advances in Characterizing Natural Products that Regulate Autophagy
Anti-Cancer Agents in Medicinal Chemistry Anti-Inflammatory Properties of Acetylcholinesterase Inhibitors Administred in Alzheimers Disease
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Preface
Current Molecular Medicine Psychomotor Seizure Test, Neurotoxicity and in vitro Neuroprotection Assay of some Semicarbazone Analogues
Central Nervous System Agents in Medicinal Chemistry Lower Frequency of co-Morbid Medical Disorders Related to Poor Impulse Control in Parkinson’s than Alzheimer’s Disease
Current Aging Science Inhibition of Opioid Receptor Mediated G-Protein Activity After Chronic Administration of Kynurenic Acid and its Derivative without Direct Binding to Opioid Receptors
CNS & Neurological Disorders - Drug Targets Conventional and Non-Conventional Targets of Natural Products in the Management of Diabetes Mellitus and Associated Complications
Current Medicinal Chemistry Flavonoids as Promising Lead Compounds in Type 2 Diabetes Mellitus: Molecules of Interest and Structure-Activity Relationship
Current Medicinal Chemistry Full Kinetics and a Mechanistic Investigation of the Synthesis of Tetrahydrobenzo[ b]pyrans in the Presence of Sodium Acetate as a Catalyst by a One-pot Three-component Reaction
Letters in Organic Chemistry Strategies to Improve the Functions and Redox State of the Immune System in Aged Subjects
Current Pharmaceutical Design Polyphenols and Stem Cells for Neuroregeneration in Parkinson’s Disease and Amyotrophic Lateral Sclerosis
Current Pharmaceutical Design FK506-Binding Proteins and Their Diverse Functions
Current Molecular Pharmacology Aluminum Vaccine Adjuvants: Are they Safe?
Current Medicinal Chemistry Autologous Mesenchymal Stem Cell Therapy in Progressive Multiple Sclerosis: An Open Label Study
Current Stem Cell Research & Therapy Emerging Therapeutic Targets in Regenerative Medicine for the Treatment of Diabetes Mellitus: A Patent Literature Review
Recent Patents on Regenerative Medicine Humanin; A Defender Against Alzheimers Disease?
Recent Patents on CNS Drug Discovery (Discontinued) Multi-Target Directed Drugs: A Modern Approach for Design of New Drugs for the treatment of Alzheimer’s Disease
Current Neuropharmacology The Concept of Depression as a Dysfunction of the Immune System
Current Immunology Reviews (Discontinued) Therapeutic Targets for the Management of Peripheral Nerve Injury- Induced Neuropathic Pain
CNS & Neurological Disorders - Drug Targets